Treatment Patterns and Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer in a Real-world Clinical Practice Setting in the United States-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Treatment Patterns and Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer in a Real-world Clinical Practice Setting in the United States

Published:2020-08 Issue:4 Volume:18 Page:284-294
ISSN:1558-7673
Container-title:Clinical Genitourinary Cancer
language:en
Short-container-title:Clinical Genitourinary Cancer

Author:

George Daniel J.,Sartor Oliver^ORCID,Miller Kurt,Saad Fred,Tombal Bertrand,Kalinovský Ján,Jiao Xiaolong,Tangirala Krishna,Sternberg Cora N.,Higano Celestia S.

Funder

Acerta Pharmaceuticals

American Association for Cancer Research

Astellas

AstraZeneca

Axess Oncology

Bayer

BMS

Calithera

Capio Biosciences

EMD Serono

Exelixis

Flatiron

Ipsen

IroGPO

Janssen

Leidos Biomedical Research

Merck Sharp & Dohme

Michael J Hennessey Associates

Millennium Med Publishing

Modra Pharmaceuticals

Myovant Sciences

NCI Nektar Therapeutics

Novartis

Pfizer

Physician Education Resource

Sanofi

UroToday

Vizuri Health Sciences

Bellicum

Blue Earth Diagnostics, Inc.

Bristol Myers Squibb

Celgene

Constellation

Dendreon

Innocrin

Invitae

Johnson & Johnson

Merck

Myovant

SOTIO

Amgen

Ferring

Sanofi-Genzyme

Publisher

Elsevier BV

Subject

Urology,Oncology

Reference29 articles.

1. Optimal treatment sequence for metastatic castration-resistant prostate cancer;Lorente;Eur Urol Focus,2016

2. Alpha emitter radium-223 and survival in metastatic prostate cancer;Parker;N Engl J Med,2013

3. Abiraterone and increased survival in metastatic prostate cancer;de Bono;N Engl J Med,2011

4. Enzalutamide in metastatic prostate cancer before chemotherapy;Beer;N Engl J Med,2014

5. Abiraterone in metastatic prostate cancer without previous chemotherapy;Ryan;N Engl J Med,2013

Cited by 104 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment Patterns and Survival Outcomes Among Androgen Receptor Pathway Inhibitor-Experienced Patients With Metastatic Castration-Resistant Prostate Cancer;Clinical Genitourinary Cancer;2024-12

2. Real-life Data on First- and Second-Line Treatment of Metastatic Castration-Resistant Prostate Cancer With Abiraterone, Enzalutamide and Cabazitaxel – A multicentric Study From Portugal;Clinical Genitourinary Cancer;2024-12

3. Impact of time to metastatic disease onset and extent of disease volume across metastatic hormone-sensitive and castration-resistant prostate cancer;Urologic Oncology: Seminars and Original Investigations;2024-11

4. Outcomes of First-Line Abiraterone Acetate or Enzalutamide for Older Adults With Metastatic Castration-Resistant Prostate Cancer According to Use of Upfront Docetaxel for Metastatic Castration-Sensitive Prostate Cancer in an International Multicenter Registry: A SPARTACUSS—Meet-URO 26 Study;Clinical Genitourinary Cancer;2024-08

5. Treatment patterns for patients with BRCA1/2-positive metastatic castration-resistant prostate cancer;The Oncologist;2024-07-31

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3